Page 11 - Collaborative Group News Today

Early in the COVID-19 pandemic, the RECOVERY trial showed that anti-inflammatory therapy with 6 mg daily dexamethasone improved survival in patients requiring oxygen supplementation.1 Additional anti-inflammatory therapy with either interleukin-6 (IL-6) inhibitors or the Janus kinase inhibitor baricitinib was later shown to provide further benefit to such patients.2,3 However, because IL-6 inhibitors and Janus kinase inhibitors might be less appropriate for some patients (eg, those who are pregn...

In patients hospitalised for COVID-19 with clinical hypoxia who required either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared with usual care, which included low-dose corticosteroids. The RECOVERY trial continues to assess the effects of higher dose corticosteroids in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Florida reported 68 local dengue cases in 2022, mostly from Miami-Dade County.

Researchers are also assessing if there are any benefits of a higher corticosteroid dose for patients on ventilators.

Vaccine makers say the vaccine can mass produced at a moderate cost, which could help ease the significant malaria burden in African countries.

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

An international group of physicians has issued a list of 31 treatment recommendations for patients diagnosed with early-onset colorectal cancer (before 50 years of age).

The FDA has accepted the sNDA for empagliflozin to reduce the risk of kidney disease progression and CV death in adults with chronic kidney disease.

Data confirms the 10-year screening colonoscopy interval is safe for average-risk adults and can be extended in some subgroups, supporting the possibility of personalized, risk-adapted CRC screening.

The FDA has accepted the sNDA for empagliflozin to reduce the risk of kidney disease progression and CV death in adults with chronic kidney disease.